| |
|
|
|
|
|
 |
| |
|
¶óº¹¼¾Á¤(¿°»êÇö󺹼¼ÀÌÆ®) LAVOXEN TABS.[Flavoxate HCl]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
669901010[A60650051]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2015.08.01)(ÇöÀç¾à°¡)
\123 ¿ø/1Á¤(2014.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹ÌȲ»öÀÇ ¿øÇü Çʸ§ÄÚÆÃÁ¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
100,500TABS |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 200¹Ð¸®±×·¥ |
500 Á¤ |
º´ |
8806699010106 |
8806699010137 |
|
| 200¹Ð¸®±×·¥ |
100 Á¤ |
º´ |
8806699010106 |
8806699010120 |
|
| 200¹Ð¸®±×·¥ |
30 Á¤ |
º´ |
8806699010106 |
8806699010113 |
|
|
| ÁÖ¼ººÐÄÚµå |
159201ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ Áúȯ¿¡ ¼ö¹ÝµÇ´Â ºó´¢ ¹× ÀÜ´¢°¨ : ½Å°æ¼ººó´¢, ¸¸¼º Àü¸³¼±¿°, ¸¸¼º ¹æ±¤¿°
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
Çö󺹼¼ÀÌÆ®¿°»ê¿°À¸·Î¼ 1ȸ 200mg 1ÀÏ 3ȸ °æ±¸Åõ¿©ÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à¿¡ °ú¹ÎÁõ ȯÀÚ
2) À¯¹® ¶Ç´Â ½ÊÀÌÁöÀåÆó»ö, À̿ϺҴÉ, Æó»ö¼º ÀåÀÇ º´¼Ò³ª ÀåÆó»öÁõ, À§Àå°ü ÃâÇ÷, ¿ª·ù¼º ½Äµµ¿° ȯÀÚ
3) ÇϺοä·ÎÀÇ Æó»ö¼º ¿ä·ÎÁúȯ ȯÀÚ
4) ºÎÁ¤ºó¸Æ ȯÀÚ |
| ½ÅÁßÅõ¿© |
1) ³ì³»Àå ȯÀÚ
2) °£Àå¾Ö ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ
3) 100mLÀÌ»óÀÇ ÀÜ´¢Çü¼º ȯÀÚ |
| ÀÌ»ó¹ÝÀÀ |
1) ¼Òȱâ°è : ¶§¶§·Î À§ºÎºÒÄè°¨, ½Ä¿åºÎÁø, ±¸¿ª, ±¸Åä, ±¸°¥, ¼³»ç, º¯ºñ µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) °ú¹ÎÁõ : ¶§¶§·Î ¹ßÁø, °¡·Á¿ò ¹× ´Ù¸¥ ÇǺκ´ ¶Ç´Â Ãʰí¿(hyperpyrexia) µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
3) Á¤½Å½Å°æ°è : µå¹°°Ô Á¹À½, ºÒ¸é, µÎÅë, ¾îÁö·¯¿ò, ¸¶ºñ°¨, ½Å°æ°ú¹Î µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) ´« : µå¹°°Ô ´«ÀÇ ÇǷΰ¨, ¾È¾ÐÇ×Áø, ½Ã·ÂÀå¾Ö¿Í ¾ÈÁ¶ÀýÀå¾Ö, ¾È±äÀåÀÇ Áõ°¡°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) Ç÷¾×°è : µå¹°°Ô È£»ê±¸Áõ´Ù ¹× ¹éÇ÷±¸°¨¼ÒÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
6) ¼øÈ¯±â°è : ºó¸Æ, ½É°èÇ×ÁøÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
7) °£Àå : µå¹°°Ô °£Àå¾Ö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
8) ºñ´¢±â°è : µå¹°°Ô ¹è´¢°ï¶õ, ¿äÆó»öÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
9) ±âŸ : ¶§¶§·Î ÇϺ¹ºÎÆØ¸¸°¨, ¾È¸é¿°¨, µå¹°°Ô µÎ±Ù°Å¸², ÈäºÎºÒÄè°¨, ¿°¨, ÀεκÎÀÌȰ¨, ½®¸ñ¼Ò¸® µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) ¾Æ¸¸Å¸µò, Äû´Ïµò, 3ȯ ¹× 4ȯ°è Ç׿ì¿ï¾à, ½Å°æ ÀÌ¿ÏÁ¦¿Í º´¿ëÅõ¿©½Ã ÀÌ ¾àÀÇ Ç×Äݸ°¼ºÈ¿°ú°¡ Áõ°¡µÉ ¼ö ÀÖ´Ù.
2) µµÆÄ¹Î±æÇ×Á¦(¿¹ : ¸ÞÅäŬ·ÎÇÁ¶ó¹Ìµå)¿Í º´¿ëÅõ¿©½Ã À§Àå¿îµ¿¿¡ ´ëÇÑ ÀÛ¿ëÀÇ »óÈ£¾àȸ¦ ÃÊ·¡ÇÒ ¼ö ÀÖ´Ù.
3) ÀÌ ¾àÀº Á¦»êÁ¦¿Í ÇÔ²² º¹¿ë½Ã È¿°ú°¡ °¨¼ÒµÉ ¼ö ÀÖ´Ù. |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| ÁÖ¼ººÐÄÚµå |
159201ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| ´ëÇ¥ÄÚµå |
8806699010106 |
| BIT ¾àÈ¿ºÐ·ù |
ºñ´¢»ý½Ä±â°è ÆòȰ±Ù ÀÌ¿ÏÁ¦ (Genito-Urinary Smooth Muscle Relaxants)
|
| ATC ÄÚµå |
Flavoxate / G04BD02
[ÄÚµåºÐ·ù»ó¼¼¼³¸í]
[ATCÄÚµå¿¹Ãø]
|
| º¹ÁöºÎºÐ·ùÄÚµå |
259 (±âŸÀÇ ºñ´¢»ý½Ä±â°ü ¹× Ç×¹®¿ë¾à )
|
| ÀǾàǰ ¹ÙÄÚµåÁ¤º¸ |
³»¿ëº¸±â
¶óº¹¼¾Á¤(¿°»êÇö󺹼¼ÀÌÆ®)/ A60650051
Á¦Ç°±Ô°Ý: 200¹Ð¸®±×·¥/Á¦Ç°¼ö·®: 30/Á¦Çü: Á¤
Æû¸ñ±âÁØÄÚµå: 199603320 /´ëÇ¥ÄÚµå: 8806699010106/Ç¥ÁØÄÚµå: 8806699010113
±¸¹ÙÄÚµå: 8809010777252/ºñ°í:-
¶óº¹¼¾Á¤(¿°»êÇö󺹼¼ÀÌÆ®)/ A60650051
Á¦Ç°±Ô°Ý: 200¹Ð¸®±×·¥/Á¦Ç°¼ö·®: 100/Á¦Çü: Á¤
Æû¸ñ±âÁØÄÚµå: 199603320 /´ëÇ¥ÄÚµå: 8806699010106/Ç¥ÁØÄÚµå: 8806699010120
±¸¹ÙÄÚµå: 8809010772042/ºñ°í:-
¶óº¹¼¾Á¤(¿°»êÇö󺹼¼ÀÌÆ®)/ A60650051
Á¦Ç°±Ô°Ý: 200¹Ð¸®±×·¥/Á¦Ç°¼ö·®: 500/Á¦Çü: Á¤
Æû¸ñ±âÁØÄÚµå: 199603320 /´ëÇ¥ÄÚµå: 8806699010106/Ç¥ÁØÄÚµå: 8806699010137
±¸¹ÙÄÚµå: 8809010772035/ºñ°í:-
|
ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä |
[ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä]
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Flavoxate¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Flavoxate acts as a direct antagonist at muscarinic acetylcholine receptors in cholinergically innervated organs. Its anticholinergic-parasympatholytic action reduces the tonus of smooth muscle in the bladder, effectively reducing the number of required voids, urge incontinence episodes, urge severity and improving retention, facilitating increased volume per void.
|
| Pharmacology |
Flavoxate¿¡ ´ëÇÑ Pharmacology Á¤º¸ Flavoxate is a spasmolytic flavone derivative that acts by relaxing the smooth muscle in the urinary tract. Flavoxate is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Muscarinic receptors play an important role in several major cholin-ergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion.
|
| Protein Binding |
Flavoxate¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Absorption |
Flavoxate¿¡ ´ëÇÑ Absorption Á¤º¸ Well absorbed from gastrointestinal tract.
|
| Pharmacokinetics |
Flavoxate HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : 55 ºÐ
- ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£ : 112 ºÐ
- ´ë»ç : Ȱ¼ºÇüÀÎ methyl flavoxate carboxylic acid
- ¼Ò½Ç : ½Å¹è¼³ 57%
°æ±¸¿ë·®ÀÇ 10-30%ÀÌ 6½Ã°£¸¸¿¡ ½Å¹è¼³µÊ
|
| Toxicity |
Flavoxate¿¡ ´ëÇÑ Toxicity Á¤º¸ The oral LD50 for flavoxate HCl in rats is 4273 mg/kg. The oral LD50 for flavoxate HCl in mice is 1837 mg/kg. Symptoms of overdose include convulsions, decreased ability to sweat, (warm, red skin, dry mouth, and increased body temperature), hallucinations, increased heart rate and blood pressure, and mental confusion.
|
| Drug Interactions |
Flavoxate¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Donepezil Possible antagonism of actionGalantamine Possible antagonism of actionRivastigmine Possible antagonism of action
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Flavoxate¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take without regard to meals.Food may reduce irritation.
|
| Drug Target |
[Drug Target]
|
| Description |
Flavoxate¿¡ ´ëÇÑ Description Á¤º¸ A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem]
|
| Dosage Form |
Flavoxate¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Tablet Oral
|
| Drug Category |
Flavoxate¿¡ ´ëÇÑ Drug_Category Á¤º¸ Parasympatholytics
|
| Smiles String Canonical |
Flavoxate¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1=C(OC2=C(C=CC=C2C(=O)OCCN2CCCCC2)C1=O)C1=CC=CC=C1
|
| Smiles String Isomeric |
Flavoxate¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1=C(OC2=C(C=CC=C2C(=O)OCCN2CCCCC2)C1=O)C1=CC=CC=C1
|
| InChI Identifier |
Flavoxate¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3
|
| Chemical IUPAC Name |
Flavoxate¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-10-04
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|